Novartis’s $9.7 Billion Acquisition Of The Medicines Co.

Paul, Weiss, Rifkind, Wharton & Garrison LLP acted as legal counsel for The Medicines Company. Debevoies & Plimpton LLP is advising JP Morgan Securities Inc. as financial advisor to The Medicines Co. in the transaction.

The Medicines Company (NASDAQ: MDCO) has entered into definitive agreement in which Novartis AG will acquire The Medicines Company for $85 per share in an all-cash transaction, implying a fully diluted equity value of $9.7 billion.

The transaction was unanimously approved by the Boards of Directors of both companies. Completion of the transaction is expected in first quarter of 2020, pending the successful completion of the tender offer and other customary closing conditions. Until that time, The Medicines Company will continue to operate as a separate and independent company.

Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC are acting as financial advisors to The Medicines Company.

JP Morgan Securities LLC is an investment management company that offers wealth planning, education funding, research, securities, brokerage solutions, consulting programs, and portfolio management services.

The Medicines Company (NASDAQ: MDCO) is a biopharmaceutical company with a singular, relentless focus on addressing the greatest global healthcare challenge and burden today – cardiovascular disease.

Novartis AG, a Swiss researcher and manufacturer, is a leading global medicines company that provides solutions to address the evolving needs of patients worldwide.

The Debevoise team was led by M&A partner Andrew Bab (Picture) and included M&A associates Sean Foley and Priya Soni.

Involved fees earner: Andrew Bab – Debevoise & Plimpton; Sean Foley – Debevoise & Plimpton; Priya Soni – Debevoise & Plimpton;

Law Firms: Debevoise & Plimpton;

Clients: JP Morgan Securities;

Author: Ambrogio Visconti